



MATERIAL SAFETY DATA SHEET

DEXAMETHASONE OMEGA (4 & 10 mg/mL)

(Dexamethasone Sodium Phosphate Injection USP)

Code: L0010026 (1 mL), L0010066 (5-mL) and L0010036 (25 mL) DIN: 02204266 (4 mg/mL)

Code: L0010067 (10-mL) & L0010094 (1-mL) DIN: 02204274 (10 mg/mL)

1 – IDENTIFICATION

Company: Omega Laboratories, Ltd.
Address: 11177 Hamon st.
Montreal, Canada
H3M 3E4
Telephone: (514) 335-0310
Fax: (514) 339-1407
Date Prepared: 2015-09-08

2 – INGREDIENTS

Hazardous Ingredients	CAS #	PEL	TLV	%
Benzyl Alcohol	100-51-6	N/A	N/A	1.0
Sodium Sulfite	7757-83-7	N/A	5 mg/m ³	-
Other Ingredients				
Dexamethasone	2392-39-4	N/A	N/A	0.4 / 1
Sodium Phosphate				
Sodium Citrate	6132-04-3	N/A	N/A	-
Dihydrate				
Water for Injection	7732-18-5	N/A	N/A	q.s.

3 - PHYSICAL DATA

Boiling Point: > 100°C (> 212°F)
Specific Gravity: > 1.000
Vapor Pressure (mm Hg/20°C): Not available.
Vapor Density (air = 1): Not available.
Evaporation Rate: Approximately water rate.
Solubility in Water: Totally soluble.
pH: 7.0 - 8.5
Appearance: Clear, colorless to pale yellow and odorless liquid.

4 - FIRE AND EXPLOSION HAZARD DATA

Flash Point (and method): Not established.
Flammability: Not considered to be a fire hazard.
Conditions of flammability: Not established.
Flammable Limits: Not established.
Auto-ignition temperature: Not established.
Extinguishing Media: Not established.
Special Fire Fighting Procedures: Not established.
Sensitivity to static discharge & Explosive power: Not established.

5 - REACTIVITY DATA

Stability: This product is stable when stored between 15 and 30°C, protected from light, heat and freezing.
Incompatibility (material to avoid): Oxidizing Agents, strong acids and caustics.
Conditions to Avoid: Heat, freezing, light exposure and contact with incompatible chemicals.
Hazardous Polymerization: Will not occur.

6 - HEALTH HAZARD ASSESSMENT

Routes of Entry: Ingestion and injection.
Injection: Local redness and pain. Cushing's syndrome, water retention, electrolyte imbalance, hypertension, hyperglycemia, myopathy and suppression of adrenal gland secretions may occur.
Ingestion: Slightly toxic based on animal data. Possible allergic reaction due to the sulfite present in the solution.
Skin and eyes: Mild irritation. Stinging, watering and redness of the eyes, itching, burning sensation on skin. May cause allergic reaction.
Signs and Symptoms of Exposure:
Chronic: Effects on the adrenal glands and immune system.
Acute: Eyes and skin irritation.

7 - EMERGENCY PROCEDURES

Skin: Rinse with water and soap for at least 15 minutes.
Eyes: Rinse with water for at least 15 minutes.
Inhalation: Remove to fresh air. Oxygen administration, if needed.
Ingestion: Flush out mouth with water. If conscious, DO NOT INDUCE VOMITING.

8 - TOXICOLOGICAL INFORMATION

Dexamethasone Sodium Phosphate:
LD₅₀ oral, mouse: 1800 mg/kg LD₅₀ IV, mouse: 112 mg/kg.
Benzyl Alcohol: LD₅₀ oral, rat: 1230 mg/kg
Considered as tumorigen and mutagen agent and may cause reproductive effects.
Sodium Sulfite: LD₅₀ oral, mouse: 820 mg/kg
Sodium Citrate Dihydrate:
LD₅₀ IV, rabbit: 449 mg/kg LD₅₀ IV, mouse: 170 mg/kg

9 - PRECAUTION INFORMATION

Steps to be taken in case material is released or spilled: Contain spill and soak up liquid with absorbent material.
Waste Disposal Method: Dispose of waste in respect with all regulatory agencies and laws.
Precautions to be taken in Handling and Storing: Store between 15 and 30°C protected from light, heat and freezing.
Other Precautions: Eyewash station and shower in working area.

10 - CONTROL MEASURES

Respiratory Protection (Specify Type): Not necessary.
Ventilation: Local Exhaust & Mechanical (General): Not necessary.
Protective Gloves: Disposable latex, nitrile, or rubber gloves.
Eye Protection: Not necessary.
Other Protective Clothing or Equipment: Lab coat.

11 - TRANSPORT INFORMATION

Not DOT Regulated.